Nkarta, a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies, reported a net loss of $40.4 million for the second quarter ended June 30, 2026. The loss per share stood at $0.54 for both basic and diluted shares, missing the analyst consensus estimate of $(0.38) by 42.11 percent. This result represents a 74.19 percent increase in losses compared to $(0.31) per share from the same period last year. The widening deficit reflects increased operating expenses as the company advances its lead program, NKX019, through multi-center clinical trials. Nkarta holds $243.2 million in cash, cash equivalents, and investments, which management expects to fund its current operating plan into 2029.

The widening loss was primarily driven by higher research and development (R&D) and general and administrative (G&A) costs. R&D expenses rose to $29.0 million from $20.8 million in the second quarter of 2025, while G&A expenses more than doubled to $14.1 million from $6.4 million year-over-year. Total operating expenses reached $43.1 million in Q2 2026, up from $27.2 million in the prior year period. Non-cash charges totaling $11.8 million were included in the net loss, comprising $1.9 million in share-based compensation, $2.7 million in depreciation, and an $8.0 million impairment of right-of-use assets and leasehold improvements.

Clinical Program Progress

Nkarta continues to enroll patients across all indications in its Ntrust-1 and Ntrust-2 trials, which evaluate NKX019 for various autoimmune diseases including systemic sclerosis, rheumatoid arthritis, and lupus nephritis. Patients are being dosed at 4 billion cells per dose in a three-dose cycle (12 billion cells total). Following an agreement with the FDA on outpatient dosing, Nkarta has begun administering NKX019 through a network of community-based sites, broadening access beyond academic medical centers. Initial clinical data from these trials are expected to be presented at a medical conference in 2026.

Financial Performance Table

Interest income declined to $2.5 million in Q2 2026 from $4.0 million in the same period last year. For the first six months of 2026, Nkarta reported a cumulative net loss of $68.2 million, compared to $55.0 million in the first half of 2025. The company’s total assets stood at $337.6 million as of June 30, 2026, down from $404.2 million at the end of 2025, largely due to the reduction in cash and investment balances.

What the Numbers Show

The significant increase in G&A expenses, which more than doubled year-over-year, contrasts with the more moderate rise in R&D spending. While R&D grew by approximately 40%, G&A surged by over 120%, suggesting a shift in cost structure or one-time administrative expenditures. Additionally, the $8.0 million impairment charge indicates a write-down of existing assets, likely related to leasehold improvements or equipment no longer deemed valuable at their previous carrying amounts. Despite the widened net loss and the miss against analyst estimates, the substantial cash balance provides a multi-year runway, reducing near-term dilution risk for shareholders as the company awaits clinical data readouts.

Nkarta, Inc. will present updates on its investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. The presentation is scheduled for 2 p.m. ET on Tuesday, June 30, 2026. This event provides a platform for the clinical-stage biopharmaceutical company to share insights on its engineered natural killer (NK) cell therapies.

Nadhir Mahmood, President of Nkarta, will lead a fireside chat to discuss the company's advancements. The discussion will focus on the potential of CAR-NK cells to treat autoimmune conditions by harnessing the innate immune system. A simultaneous webcast will be available on the investors section of Nkarta's website, with a replay archived for approximately 90 days.

Nkarta is advancing allogeneic, off-the-shelf NK cell therapies designed for outpatient dosing in community health settings. The company aims to provide broad access to its novel cell therapies, which are engineered to eliminate pathogenic B cells driving autoimmune responses.

Key Event Details

The company's website, www.nkartatx.com , will host the live webcast and subsequent replay. Investors and interested parties can access the presentation through the investors section of the site.